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ABSTRACT
Objective To determine the association of reductions in
priceof antiretroviraldrugsandforeignassistanceforHIV
with coverage of antiretroviral treatment.
Design Retrospective study.
Setting Africa.
Participants 13 African countries, 2003-8.
Main outcome measures A price index of first line
antiretroviral therapy with data on foreign assistance for
HIV was used to estimate the associations of prices and
foreign assistance with antiretroviral coverage
(percentage of people with advanced HIV infection
receiving antiretroviral therapy), controlling for national
public health spending, HIV prevalence, governance, and
fixed effects for countries and years.
Results Between 2003 and 2008 the annual price of first
line antiretroviral therapy decreased from $1177 (£733;
€844) to $96 and foreign assistance for HIV per capita
increasedfrom$0.4to$13.8.Atan annualpriceof $100,
a $10 decrease was associated with a 0.16% adjusted
increase in coverage (95% confidence interval 0.11% to
0.20%; 0.19% unadjusted, 0.14% to 0.24%). Each
additional $1 per capita in foreign assistance for HIV was
associated with a 1.0% adjusted increase in coverage
(0.7% to 1.2%; 1.4% unadjusted, 1.1% to 1.6%). If the
annual price of antiretroviral therapy stayed at $100,
foreign assistance would need to quadruple to $64 per
capita to be associated with universal coverage.
Government effectiveness and national public health
expenditures were also positively associated with
increasing coverage.
Conclusions Reductions in price of antiretroviral drugs
were important in broadening coverage of HIV treatment
in Africa from 2003 to 2008, but their future role may be
limited. Foreign assistance and national public health
expenditures for HIV seem more important in expanding
future coverage.
INTRODUCTION
The expansion in coverage of antiretroviral therapy for
people infected with HIV in sub-Saharan Africa is both
oneofthemostremarkableaccomplishmentsandaper-
sistent concern in global public health.
12 At the begin-




3 The converging influences of
global political support, public-private partnerships,
soaring activism, proliferation of non-governmental
organisations,andimprovementsinhealthservicedeliv-
ery systems for HIV created an environment that
enabled exceptional growth in the numbers of people
receiving treatment.
45Within that milieu, two powerful
drivers—drug prices and foreign assistance—directly
influencedthequantitiesofantiretroviraldrugsavailable
to infected people in sub-Saharan Africa.
At the turn of the century the price of antiretroviral
therapy in Africa was similar to that in developed
nations, commonly upwards of $5000 (£3100;
€3600).
6 Since 2001, prices of antiretroviral drugs
have decreased dramatically through a combination
of price negotiations, generic pharmaceutical growth,
bulk purchasing, and trade agreements. By 2009 the
price for a regimen of first line antiretroviral therapy
in some places was less than $100 a year.
7 Further
reductions in the price of antiretroviral therapy, how-
ever,posea continuedchallenge ascountriesaremov-
ing towards less toxic but more expensive drugs as
preferred treatment.
8
Concurrently, resources for purchasing anti-
retroviral drugs in low income countries have
increased dramatically since the Declaration of Com-
mitment on HIV/AIDS (adopted by the United
Nations General Assembly in 2001).
9 Three large
international organisations accounted for most of the
increase in available resources: the President’s Emer-
gency Plan for AIDS Relief; the Global Fund to Fight
AIDS, Tuberculosis, and Malaria; and the World
Bank’s Multi-Country HIV/AIDS Program.
910 The
funding for HIV in low and middle income countries
—a little over $1bn in 2000 and over $15bn in 2008—
wasmostlydonatedbyhighincomecountries,withthe
United States providing the largest share.
1112 To date,
the largest portion of the funds disbursed through the
President’s Emergency Plan for AIDS Relief, Global
Fund, and World Bank has been used to provide anti-
retroviral therapy.
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eign assistance, and the enabling environment within
whichthesedriversoperated,progresstowardsachiev-
ing universal coverage is currently predicted to fall
short of the Millennium Development Goals in many
sub-Saharan African countries.
11
We explore the relations of price reductions of anti-
retroviral drugs and foreign assistance for HIV with
coverage of antiretroviral therapy for three main rea-
sons. Firstly, price reductions and foreign assistance
are important policy mechanisms and identifying
their role in expanding coverage can help in policy
formulation. Secondly, future foreign assistance for
HIVispotentiallyjeopardisedwiththeglobalfinancial
crisis and a changing perception that the burden of the




duction and the mix of recommended antiretroviral
drugsshiftsinfavourofmoreexpensivedrugs.Under-
standing these relations provides an important bench-




We calculated a price index for first line antiretroviral
therapy at country and year level for 13 countries in
sub-Saharan Africa from 2003 to 2008. Our price
datacameprimarilyfromtheWorldHealthOrganiza-
tion Global Price Reporting Mechanism and the
ARNS Economics of AIDS and Access to HIV/
AIDS Care in Developing Countries Project.
1415 Both
sources collected data on prices directly from national
AIDS programmes and other major purchasers and
published transactional data such as quantities pur-
chased, dosages, and amount paid. We used the price
information of each antiretroviral agent in each coun-
try andyeartocalculatea priceindex,weightedbythe
quantity and deflated to 2008 US dollars.
16 We used
the current first line formulary in the World Health
Organization’s treatment guidelines to determine the
relevantfirstlinedrugs.
1718Fixeddosecombinationsof
two or three drugs were weighted accordingly. This
resulted in a unidimensional (2008 US dollars) price
index of first line antiretroviral therapy with observa-
tions of country and year.
Foreign assistance to purchase antiretroviral drugs
The other major economic driver of expanded anti-
retroviral coverage was foreign assistance to support
HIV programmes. We estimated foreign assistance
for HIV using public information on disbursements
(not commitments) for HIV programmes by the three
major international donor organisations: the World
Bank, Global Fund, and President’s Emergency Plan
forAIDSRelief.
19-22Weusedthosethreeorganisations
as the indicators of foreign support for scaling up anti-
retroviral therapy in Africa for two main reasons: dur-
ing the study years most antiretroviral drugs were
purchased using funds from one of these sources, and
detailed annual data are available from a consistent
source. Although other national and private donors
also contributed to expanding coverage of anti-
retroviral therapy in Africa—most notably the United
Kingdom’s Department for International Develop-
ment—their contributions have been smaller.
23
We used data on total disbursements for HIV as
opposed to expenditures specific to antiretroviral ther-
apy. Foreign assistance for HIV was used to fund anti-
retroviral therapy, HIV prevention, care of vulnerable
populations,andbuildingcapacityforlargescaledeliv-
ery of healthcare to infected people. We used total for-
eign aid for HIV because the total disbursements were
reported over time more consistently and because
activitiessuchastreatment,prevention,andcareofvul-
nerable populations often blend and have spill over
effects. Foreign assistance was weightedby the popula-
tion size for each observation of country and year.
Coverage of antiretroviral therapy
Weusedpublishedestimatesofantiretroviralcoverage
from the joint United Nations programme on
HIV/AIDS (UNAIDS) for each country and year.
24-27
Coverage is defined as the percentage of adults and
children with advanced HIV infection receiving anti-
retroviral therapy. The number of people receiving
antiretroviraltherapyisreportedbymembercountries
and undergoes a reconciliation process.
28-30 The esti-
mates of people with advanced HIV come from the
UNAIDS reference group on estimates, modelling,
and projections, as reported in the epidemiological
fact sheets on HIV/AIDS for each country.
2731
Statistical analysis
We constructed a panel dataset with annual prices of
first line antiretroviral therapy (2008 US dollars), for-
eign assistance for HIV (2008 US dollars per capita),
and antiretroviral coverage (percentage) for the years
2003 to 2008 for all African countries that had com-
plete longitudinal data on price and antiretroviral cov-
erage. The unadjusted analysis examined the




Population (millions) 32.8 (35.0) 34.3 (36.7) 36.9 (40.2)
Antiretroviral coverage (%) 5.7 (4.6) 16.2 (15.3) 51.2 (23.6)
Price of first line antiretroviral therapy (2008 $) 1177 (508) 708 (244) 96 (18)
Foreign assistance for HIV per capita (2008 $)* 0.42 (0.49) 6.6 (8.2) 13.8 (16.1)
HIV prevalence (%) 10.1 (6.3) 9.6 (5.9) 9.3 (5.6)
Public health expenditures per capita (2008 $)† 23.7 (36.1) 32.5 (52.7) 40.9 (55.8)
Public health expenditures (% of gross domestic product) 3.1 (2.2) 3.2 (1.7) 3.4 (2.0)
Living in cities, 2008 (%) 30.5 (14.8) 31.4 (15.1) 32.8 (15.5)
Per capita gross domestic product 783 (1066) 1043 (1539) 1306 (1673)
Government effectiveness index‡ −0.55 (0.15) −0.52 (0.19) −0.47 (0.18)
*Total resources disbursed for HIV from three major international donors (World Bank, Global Fund, and
President’s Emergency Plan for AIDS Relief) per capita.
†Using World Bank’s estimates of public health expenditures as percentage of gross domestic product, gross
domestic product, and population to estimate per capita expenditures.
‡Raw score from World Bank governance matters index (approximate range −2.5-2.5), with higher scores
reflecting better governance.
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independent variables and antiretroviral coverage as
the dependent variable in a generalised linear model
regression. Our adjusted analyses included time vary-
ing covariates, a price squared term to allow for a non-
linear relation between price and coverage, and fixed
effectsforcountryandyear.Countryfixedeffectscon-
trol for differences between countries that are constant
over time, whereas year fixed effects control for com-
mon changes over time.
32 Our time varying covariates
aim to represent the environment within which price
reductions and foreign assistance operated and which
could have independently affected coverage. These
include several epidemiological variables, economic
measures, and governance indicators (box).
Weusedtheadjustedmodelforseveralcalculations.
We explored the sensitivity of antiretroviral coverage
to changes in price. Because the association of prices
and coverage is non-linear (quadratic), coverage is dif-
ferentially sensitive to changes in price at different
price points. We provide estimates of that association
at several illustrative price points. We then estimated
the increasein coverage explainedby pricereductions
by holding all model inputs other than prices fixed at
their 2003 values, and predicted coverage at 2008. We
repeated the analysis for assistance and calculated the
portion of the increase in coverage explained by each
of these mechanisms. In addition we estimated the
resources required for universal coverage at different
prices for antiretroviral drugs, levels of foreign assis-
tance,andnationalpublichealthexpenditures.Finally,
we calculated the benefits in terms of life years gained




Thirteen countries with complete information on
prices, foreign assistance, and antiretroviral coverage
from 2003 to 2008 were studied: Cameroon, Ethiopia,
Kenya, Malawi, Mozambique, Namibia, Nigeria,
Rwanda, South Africa, Tanzania, Uganda, Zambia,
and Zimbabwe. These countries represent about 60%
of Africa’s population and 84% of Africa’s estimated
number of people living with HIV/AIDS.
In 2003 the mean annual price of first line anti-
retroviral therapy in the study countries was $1177
(SD $508) per capita and the average coverage of anti-
retroviral treatment was 5.7% (SD 4.6%). By 2008 the
mean annual price of first line antiretroviral therapy
haddecreasedto$96.1,withsubstantiallylessvariabil-
ity (SD $18.1). During the same period, antiretroviral
coverage increased to 51.2% on average (SD 23.6%).
National public health expenditures per capita
increased from $23.7 in 2003 to $40.9 in 2008
(P=0.42), although those expenditures were less differ-
ent when expressed as a percentage of gross domestic
product (3.1% in 2003 and 3.4% in 2008, P=0.75).
Table 1 shows the descriptive variables of the study
countries.
The unadjusted model relating price and foreign
assistance to coverage shows a strong association of
coverage with both variables. From 2003 to 2008,
every $10 decrease in the price of first line anti-
retroviraltherapywasassociatedwitha0.19%increase
in coverage (95% confidence interval 0.14% to 0.25%,
P<0.001). Figure 1 shows the association of annual
price of first line antiretroviral therapy per capita in
2008 US dollars and antiretroviral coverage. Two
important observations are notable: firstly, price
reductions were associated with greater increases in
antiretroviral coverage at lower prices and, secondly,
the annual prices decreased only modestly and con-
verged to a narrow range of prices between 2007 and
2008. The adjusted model includes a non-linear
(squared) relation, with price and adjustments for
HIV prevalence, per capita national public health
expenditures, urban status, per capita gross domestic
product, government effectiveness, country fixed
effects, and year fixed effects. Using this model, price
reductions had a changing association with
Time varying covariates that potentially could affect coverage of HIV treatment
 HIV prevalence—changing burden of disease could have an independent and effect
modifying relation with treatment coverage
33
 Urbanisation—represented as the percentage of the population noted to live in urban
areas and is a proxy for ease of access to clinics and healthcare facilities
34
 Per capita health expenditures—calculated using health expenditures as a percentage
of gross domestic product×gross domestic product/population), and explores the
contribution of in-country health expenditures to increasing coverage
34
 Per capita gross domestic product in current US dollars (in purchasing power parity)—
a general measure of economic capacity and development status
34
 Government effectiveness index (using World Bank Governance Matters database)—
examines whether changes in governance help explain coverage
35
Thus, the adjusted analysis used a generalised linear model with a normal (Gaussian) link
function of the following form:









































Fig 1 | Relation between price of first line antiretroviral therapy
and coverage. Points represent country and year estimate of
price of therapy in 2008 US dollars and antiretroviral coverage
during that year. Markers are differentiated by year of
observation to show price trends of therapy. Quadratic fit line
suggests greater increases in coverage associated with price
reductions at low prices, but coverage averaging just over
50% with lowest observed prices. In addition, prices appear
to converge, so that by 2008 the prices are similar in most
countries, suggesting a floor effect for price reductions
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price of $500, every $10 decrease in the price of anti-
retroviraltherapywasassociatedwitha0.04%increase
in coverage (95% confidence interval 0.02% to 0.06%,
P=0.01),andatanannualpriceof$100,a$10decrease
was associated with a 0.16% increase in coverage
(0.11% to 0.20%, P=0.01).
Foreign assistance for HIV was also closely asso-
ciated with antiretroviral coverage. Each additional
$1 per capita in foreign assistance was associated with
a 1.4% increase in antiretroviral coverage (1.1% to
1.6%, P<0.001) in the unadjusted model and 1.0%
(0.7%to1.2%,P<0.001)intheadjustedmodel.Several
adjusters were associated with increased coverage: per
capita national public health expenditures, govern-
ment effectiveness score, and HIV prevalence (non-
significant trend). Figure 2 shows the association
between foreign assistance and coverage, and table 2
shows the associations for the fully adjusted model.
The foreign assistance required for universal cover-
agewasestimatedusingtheadjustedmodelbyholding
thevaluesforallcovariatesotherthanassistance,fixed
at their 2008 levels. Using this approach, at an annual
price of $100 for first line antiretroviral therapy and
current national public health expenditures, foreign
assistance for HIV would have to be about $64 per
capita to reach universal coverage. Among the study
countries, only one (Namibia) approaches that level of
expenditures. The total assistance required to reach
universal coverage in the 13 study countries is esti-
mated at $14.8bn. At an annual price of $100 for first
line antiretroviral therapy and foreign assistance for
HIV per capita at the 2008 mean ($13.8), the national
public health expenditures associated with universal
coverage are $109 per capita, nearly three times cur-
rent levels. Figure 3 shows the calculated relation
between foreign assistance and national public health
expendituresassociatedwithuniversalcoverageatdif-
ferent price points. Price reductions alone without
further increase in public health expenditures or for-
eign assistance for HIV were associated with a maxi-
mum coverage of 55.8% at an annual price of $1.
Theportionoftheincreaseincoverageexplainedby
prices and assistance was estimated with a thought
experiment: if everything remained at 2003 levels
except for prices, what would the predicted coverage
be in 2008? This was repeated for assistance, and the
portionofthepredictedincreaseincoveragewitheach
was calculated. Using this approach prices were esti-
mated to be associated with 20.4% of the predicted
increase in coverage and foreign assistance with
29.1% of the increase.
Finally, the mortality benefits of price reductions
and foreign assistance were calculated. Antiretroviral
therapy in sub-Saharan Africa was estimated to pro-
long life by 4.0-12.1 years, and 4.8 million people




antiretroviral drugs was associated with 36480-
110352 yearsoflifesaved.Usinga similarcalculation,
each additional $1 per capita in foreign assistance for
HIV ($480m for the total study population) was asso-
ciated with 268800-813120 years of life saved, or
$590-$1784 per year of life saved.
DISCUSSION
Our analysis of the relation between price reductions
of antiretroviral drugs, foreignassistance for HIV, and
the expansion of antiretroviral coverage in 13 African
countriesshedslightontwoofthemostimportantpol-
icy mechanisms associated with expanded coverage:
pricereductionsandforeignassistance.Theexpansion
in coverage was closely linked to both between 2003
and 2008. Our estimates suggest that price reductions
to even low levels are unlikely to be associated with






















































Fig 2 | Relation between foreign assistance and coverage.
Foreign assistance is in 2008 US dollars distributed for HIV by
three major international donors (President’s Emergency Plan
for AIDS Relief, Global Fund, and World Bank) per capita in
each country during year of interest. Markers are
differentiated by year of observation, and quadratic fit curve is
shown
Table 2 |Impact of price reductions, foreign assistance, and development and governance






Reducing price of first line antiretroviral drugs by $10 0.19 (0.14 to 0.25)
***
Annual price $500 0.04 (0.02 to 0.06)**
Annual price $100 0.16 (0.11 to 0.20)**
Increasing foreign assistance per capita by $1 1.4 (1.1 to 1.6)*** 1.0 (0.7 to 1.2)***
$1 increase in public health expenditures§ — 0.7 (0.05 to 1.4)*
1% increase in proportion living in urban areas — -2.2 (-5.6 to 1.2)
1% higher HIV prevalence — 1.2 (-0.3 to 2.7)
Per capita gross domestic product higher by $100 — -0.4 (-0.9 to 0.1)
Each 1 point increase in government effectiveness¶ — 0.4 (0.1 to 0.7)**
*Significant at 0.05; **significant at 0.01; ***significant at 0.001.
†Unadjusted model includes prices of first line antiretroviral drugs and foreign assistance for HIV expressed in
2008 dollars per capita.
‡Adjusted for HIV prevalence, per capita health expenditures, urban status, per capita gross domestic product,
government effectiveness, country fixed effects, and year fixed effects; and includes price squared term to allow
non-linear relation with coverage. Country fixed effects control for unobserved country differences that do not
vary over time, and year fixed effects control for unmeasured differences that affect countries to same degree
over time.
§Measured as overall expenditures for health from national sources in 2008 dollars per capita.
¶Measured using World Bank governance matters index.
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a particular appeal as a policy target for expanding
antiretroviral coverage. Price reduction operates
through a market mechanism and it may reduce the
reliance on uncertain cycles of foreign assistance.
However, the effectiveness of price reductions is lim-
itedbythreeimportantconsiderations.Firstly,wenote
thatfurtherreductionsbelowthecurrentlowpricesare
unlikely to be associated with universal coverage. Sec-
ondly, we note that prices of first line antiretroviral
therapy converged around a price that possibly repre-
sents something close to the lowest sustainable price.
Finally, clinically appropriate considerations are shift-
ingthemixofantiretroviraldrugsinuseinAfrica,rais-
ing doubts about future price reductions. High rates of
toxicity, increasing use of second line antiretroviral
drugs, and difficult dosing schedules of previously
recommended antiretroviral regimens are leading to
changes in the mix in favour of clinically superior,
but also more expensive, drugs.
Understanding the role of price reductions and for-
eign assistance is pertinent at a time when continued
assistanceforHIVisthreatenedasaresultoftheglobal
financialcrisis.Foreignassistancefromgovernmentsis
often linked to national budgets, and the economic
downturn may have implications for assistance with
HIV.Foreignassistanceisalsothreatenedbythechan-
ging perception of the HIV epidemic. Many successes
in increasing assistance for HIV occurred in response
to the perception of HIV as a humanitarian, diplo-
matic, security, and development crisis in Africa.
38 As
the epidemic is stabilising in many parts of sub-
SaharanAfrica,thatperceptionischanging.
39Ourana-
lysis shows, however, that if universal coverage is a
soughtaftergoal,foreignassistanceandnationalpublic
health expenditures should increase substantially,
especially as the criteria for initiating antiretroviral
therapy are liberalised.
40
Limitations of the study
Severallimitationsareimportanttonote.Weusedcon-
tributionsforHIVfromtheWorldBank,GlobalFund,
and President’s Emergency Plan for AIDS Relief to
measure foreign assistance for HIV. Although these
organisations provide the largest share of the available
fundsforpurchasingantiretroviraldrugs,thismeasure
is limited in two ways. Firstly, it does not take into
accounttheproliferationincontributionsandactivities
from non-governmental organisations, which
occurred over the same period. Secondly, we lumped
all assistance for HIV together without accounting for
thedifferentactivitiessupportedbyHIVfunding,such




drugsdecrease,the costs of delivering therapy, such as
laboratory monitoring, supply chain, and human
resources are taking an ever greater role. In addition,
the transactional prices we collected do not represent
the price at the point of care, and our analysis is most
relevant at a societal level. We focused on the price of
first line antiretroviral drugs and did not include more
expensive first or second line drugs; however, the
increasing use of more expensive drugs underscores
the possible future role of price reductions. Finally,
many of our calculations rely on extrapolations of the
data from 2003 to 2008, and our estimates therefore
assume stable relations among the various factors con-
tributing to antiretroviral coverage.
Policy implications
We provide the first exploration on the relation
between price of first line antiretroviral therapy, for-
eign assistance for HIV, and antiretroviral coverage,
andsuggestthatfurtherpricereductionshavealimited
potential in further expanding antiretroviral coverage.
Rather, further expansion will depend almost entirely
on increasing expenditures from foreign donors or
domestic sources.
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Fig 3 | Resource requirements for universal coverage.
Combination of foreign assistance for HIV per capita and
national public health expenditures estimated to be sufficient
for universal coverage at difference price points of first line
antiretroviral therapy. As of 2008, public health expenditures
in study countries were $40.9 per capita and foreign
assistance for HIV $13.8 per capita
WHAT IS ALREADY KNOWN ON THIS TOPIC
The expansion of antiretroviral coverage has been a major accomplishment of the global
health community since the turn of the century
This expansion was aided in part by increasing foreign assistance and decreasing prices of
antiretroviral drugs
The relations among these drivers of treatment expansion and the contribution of national
public health expenditures were, however, not known
WHAT THIS STUDY ADDS
Prices of antiretroviral drugs and foreign assistance were both closely linked to expanded
coverage
Price reductions approach a plateau, however, and may start increasing
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